For people who were commenced on b/tsDMARDs for RA, Wales had the highest proportion of individuals prescribed b/tsDMARDs other than TNF inhibitors at 12 months (40.0%, compared with 13.0% to 29.9% throughout regions of England; Table 1). The gene discussed is TNF; the disease is rheumatoid arthritis.